Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>Pazopanib Hydrochloride

Pazopanib Hydrochloride

Pazopanib Hydrochloride Structure
Pazopanib Hydrochloride structure
CAS No.
635702-64-6
Chemical Name:
Pazopanib Hydrochloride
Synonyms
Pazopanib hydrochloride;Pazopanib HCl;ArMala;786034;CS-462;GW-786034B;GW786034 HCl;Votrient HCl;Pazopanib HCI;Unii-33Y9anm545
CBNumber:
CB42495435
Molecular Formula:
C21H24ClN7O2S
Molecular Weight:
473.98
MDL Number:
MFCD12546138
MOL File:
635702-64-6.mol
MSDS File:
SDS
Last updated:2024-03-29 11:48:57
Request For Quotation

Pazopanib Hydrochloride Properties

Melting point >290°C (dec.)
storage temp. Hygroscopic, Refrigerator, under inert atmosphere
solubility Acetonitrile (Slightly), DMSO (Slightly)
form Yellow powder.
color White to Off-White
Stability Hygroscopic
NCI Dictionary of Cancer Terms pazopanib hydrochloride
FDA UNII 33Y9ANM545
NCI Drug Dictionary pazopanib hydrochloride

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H332-H335
Precautionary statements  P261-P280-P305+P351+P338

Pazopanib Hydrochloride price More Price(32)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich SML3076 Pazopanib hydrochloride ≥98% (HPLC) 1149669-28-2 10MG $86.1 2022-05-15 Buy
Sigma-Aldrich SML3076 Pazopanib hydrochloride ≥98% (HPLC) 1149669-28-2 50MG $348 2022-05-15 Buy
ChemScene CS-0126 PazopanibHydrochloride 99.84% 635702-64-6 500mg $420 2021-12-16 Buy
ApexBio Technology A8347 PazopanibHydrochloride 635702-64-6 500mg $480 2021-12-16 Buy
ChemScene CS-0126 PazopanibHydrochloride 99.84% 635702-64-6 1g $552 2021-12-16 Buy
Product number Packaging Price Buy
SML3076 10MG $86.1 Buy
SML3076 50MG $348 Buy
CS-0126 500mg $420 Buy
A8347 500mg $480 Buy
CS-0126 1g $552 Buy

Pazopanib Hydrochloride Chemical Properties,Uses,Production

Description

Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is an oral second-generation multitarget TKI developed by GSK and approved for marketing by the FDA in 2009 and the EMA in 2010. It targets the VEGFR, platelet-derived growth factor receptor, and c-kit, key proteins responsible for tumor growth and survival. It is used to treat patients with advanced RCC and advanced soft tissue sarcoma who have experienced chemotherapy. Pazopanib Hydrochloride has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist, a tyrosine kinase inhibitor, and an angiogenesis-modulating agent.

Originator

GlaxoSmithKline (US)

Uses

The Hydrochloride salt of Pazopanib (P210925) a oral angiogenesis inhibitor targeting VEGFR and PDGFR.

Uses

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively - See more at: http://www.selleckchem.com/products/Pazopanib-Hyd

Uses

Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

Definition

ChEBI: A hydrochloride salt prepared from equimolar amounts of pazopanib and hydrochloric acid. Used for treatment of kidney cancer.

Definition

The growth of solid tumors is dependent on angiogenesis, the process wherein new capillaries are formed from existing blood vessels. VEGF is one of the most important inducers of angiogenesis and expressed at high levels by most tumors. Hence, the inhibition of VEGF or its receptor signaling system is an attractive target for cancer therapeutics. The most studied and developed inhibitors are monoclonal antibodies that neutralize VEGF (e.g., bevacizumab), anti-VEGF ribozymes (e.g., angiozyme), and small-molecule VEGFR kinase inhibitors (e.g., sunitinib, sorafenib). Pazopanib is the latest VEGFR kinase inhibitor to reach the market. It is indicated for the oral treatment of advanced RCC. The biological functions of the VEGF family are mediated by activation of three structurally homologous tyrosine kinase receptors, VEGFR-1, VEGFR-2, and VEGFR3. In vitro, pazopanib inhibits VEGFR-1, VEGFR-2, and VEGFR-3 with IC50 values of 10, 30, and 47 nM, respectively. In addition, it inhibits several of the closely related tyrosine receptor kinases, including platelet-derived growth-factor receptor β(PDGFR-β), c-kit, and fibroblast growth factor receptor-1 (FGFR1) with IC50 values of 84, 74, and 140 nM, respectively. In human umbilical vein endothelial cells (HUVEC), pazopanib inhibits VEGF-induced proliferation more potently than basic fibroblast growth factor (bFGF)-stimulated proliferation (IC50 = 21 nM vs. 721 nM) and concentration-dependently inhibits VEGF-induced VEGFR-2 phosphorylation (IC50 = 7 nM). It also potently inhibits angiogenesis in Matrigel plug and corneal micropocket assays. The most common adverse events associated with pazopanib were diarrhea, hypertension, hair depigmentation, nausea, anorexia, and vomiting.

brand name

Votrient

Clinical Use

Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/b, and c-kit that blocks tumor growth and inhibits angiogenesis. It was approved for renal cell carcinoma by the U.S. Food and Drug Administration in 2009 and is marketed under the trade name Votrient by the drug’s manufacturer, GlaxoSmithKline.

Side effects

Pazopanib is synthesized in five chemical steps starting from 3-methyl-6-nitroindazole, which is converted to the corresponding 2,3-dimethylindazole analog via N-methylation with trimethyloxonium tetrafluoroborate. Subsequent reduction of the nitro group to the amino group using tin chloride followed by condensation with 2,4dichloropyrimidine yields a chloropyrimidinylaminoindazole intermediate. The final two steps leading up to pazopanib consist of an N-methylation reaction using iodomethane and cesium carbonate followed by condensation with 5-amino-2-methylbenzenesulfonamide.

Synthesis

The synthesis of pazopanib begins with methylation of 3-methyl-6- nitroindazole (82) with trimethyl orthoformate in the presence of BF3?¤OEt to give indazole 83 in 65% yield. Reduction of the nitro group was achieved via transfer hydrogenation to give 84 in 97% yield, and this was followed by coupling the aniline with 2,4-dichloropyrimidine in a THF-ethanol mixture at elevated temperature to provide diarylamine 85 in 90% yield. The aniline nitrogen was then methylated using methyl iodide to give 86 in 83% yield prior to coupling with 5-amino-2-methylbenzenesulfonamide (87) and salt formation using an alcoholic solution of HCl to furnish pazopanib hydrochloride (XIV) in 81% yield.

Synthesis_635702-64-6

target

VEGFR1

References

[1] Sodeifian, G. et al. “Solubility of pazopanib hydrochloride (PZH, anticancer drug) in supercritical CO2: Experimental and thermodynamic modeling.” The Journal of Supercritical Fluids 55 1 (2022): 0.
[2] “Stability Indicating HPTLC Method Development and Validation for the Estimation of Pazopanib Hydrochloride in Bulk and its Dosage Form.” International Journal of Pharmaceutical Research 18 1 (2020).
[3] K. Kawasaki . “Retrospective Safety Analysis in Advanced Soft Tissue Sarcoma Patients of Pazopanib Hydrochloride.” Annals of Oncology 24 (2013): Page ix38.
[4] Gupta, Amit and Rashmi Dahima. “Application of Simplex Lattice Mixture design and desirability function in the development and Optimization of SEDDS for protein kinase inhibitor-Pazopanib Hydrochloride.” Research Journal of Pharmacy and Technology 83 1 (2023): 0.

Pazopanib Hydrochloride Preparation Products And Raw materials

Raw materials

3-Methyl-6-nitroindazole 5-Amino-2-methylbenzenesulfonamide

Preparation Products

Pazopanib Hydrochloride Suppliers

Global( 303)Suppliers
Supplier Tel Email Country ProdList Advantage
AFINE CHEMICALS LIMITED 		0571-85134551 info@afinechem.com CHINA 15377 58
BIONNA MEDICINE CO.,LTD
01056380788-8515; +8618518759099 790226113@qq.com China 52 58
Yangzhou Qinyuan Pharmatech Co.,ltd
+86-18752526868 jennysun@yzqyyykj.com China 64 58
Beijing Cooperate Pharmaceutical Co.,Ltd 		010-60279497 sales01@cooperate-pharm.com CHINA 1811 55
Henan Tianfu Chemical Co.,Ltd. 		+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21689 55
Hangzhou FandaChem Co.,Ltd. 		008657128800458; +8615858145714 fandachem@gmail.com China 9344 55
ATK CHEMICAL COMPANY LIMITED 		+undefined-21-51877795 ivan@atkchemical.com China 32686 60
Anqing Chico Pharmaceutical Co., Ltd. 		15380796838 chloewu@chicopharm.cn CHINA 341 58
Lianyungang happen teng technology co., LTD 		15950718863 wang666xt@163.com CHINA 295 58
career henan chemical co 		+86-0371-86658258 sales@coreychem.com China 29914 58
Supplier Advantage
AFINE CHEMICALS LIMITED 		58
BIONNA MEDICINE CO.,LTD
58
Yangzhou Qinyuan Pharmatech Co.,ltd
58
Beijing Cooperate Pharmaceutical Co.,Ltd 		55
Henan Tianfu Chemical Co.,Ltd. 		55
Hangzhou FandaChem Co.,Ltd. 		55
ATK CHEMICAL COMPANY LIMITED 		60
Anqing Chico Pharmaceutical Co., Ltd. 		58
Lianyungang happen teng technology co., LTD 		58
career henan chemical co 		58

Related articles

Related Qustion

View Lastest Price from Pazopanib Hydrochloride manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Pazopanib hydrochloride pictures 2023-12-19 Pazopanib hydrochloride
635702-64-6
 US $0.00-0.00 / kg 1kg 99%，single impurity＜0.1 1 ton Nanjing Fred Technology Co., Ltd
Pazopanib HCl pictures 2023-08-16 Pazopanib HCl
635702-64-6
 US $80.00 / KG 1KG >99% 20tons Weijer International Trade (Hebei) Co., Ltd
Pazopanib hydrochloride pictures 2022-06-21 Pazopanib hydrochloride
635702-64-6
 US $0.00 / g 10g 99% 10tons Yangzhou Qinyuan Pharmatech Co.,ltd
  • Pazopanib HCl pictures
  • Pazopanib HCl
    635702-64-6
  • US $80.00 / KG
  • >99%
  • Weijer International Trade (Hebei) Co., Ltd

Pazopanib Hydrochloride Spectrum

Unii-33Y9anm545(635702-64-6)1HNMR

635702-64-6(Pazopanib Hydrochloride)Related Search:

Palonosetron Hydrochloride Afatinib 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide hydrate Cabazitaxel Lapatinib ditosylate
Afatinib dimaleate AZD-9291 Nintedanib Ethanesulfonate Salt Pazopanib 2,3-DIMETHYL-6-NITRO-2H-INDAZOLE
2,3-dimethyl-2H-indazol-6-amine hydrochloride 2-Ethyl-5-nitrobenzenamine ,98% 3-Methyl-6-nitroindazole Sorafenib tosylate Gefitinib
Axitinib Dasatinib Regorafenib

1of4

Unii-33Y9anm545 BenzenesulfonaMide, 5-[[4-[(2,3-diMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-, hydrochloride 786034 ArMala Pazopanib Hydrochloride (GW786034) 5-(4-((2,3-diMethyl-2H-indazol-6-yl)(Methyl)aMino)pyriMidin-2-ylaMino)-2-MethylbenzenesulfonaMide hydrochloride Pazopanib HCl (GW786034 HCl) Pazopanib HCI Pazopanib HCl (GW786034) 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide HCl Pazopanib HCl API Pazopanib HCl, >=99% 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidin-yl]amino]-2-methylbenzenesulfonamide monohydrochloride Pazopanib hydrochloride(API) GW786034 (Hydrochloride)) 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide,hydrochloride CS-462 GW-786034B GW-786034;GW786034;GW 786034 GW786034 HCl Votrient HCl Unii-33Y9anm545 USP/EP/BP Unii-33Y9anm545 635702-64-6 Pazopanib HCl Pazopanib hydrochloride Pazoni hydrochloride 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide hydrochloride Mosapride Impurity 2 Hydrochloride 5- (4- ((2,3-dimethyl-2H-indole-6-yl) (methyl) amino) pyrimidin-2-yl) amino) -2-methylbenzenesulfonamide hydrochloride Pazopanil hydrochloride 635702-64-6 C21H23N7O2SHCl C21H24ClN7O2S C21H23N7O2SClH HFC80011 API